| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 81, 4224-4228, Copyright © 1996 by Endocrine Society
ARTICLES |
B Biondi, S Fazio, A Cuocolo, D Sabatini, E Nicolai, G Lombardi, M Salvatore and L Sacca
Department of Internal Medicine, University Federico II Medical School, Naples, Italy.
To assess cardiac function and exercise tolerance in patients receiving long term TSH-suppressive therapy with levothyroxine (L-T4), we studied maximal exercise capacity with a bicycle ergometer and left ventricular function at rest and during physical exercise by radionuclide angiography. The evaluation was performed in 10 patients receiving L-T4 therapy (2.31 +/- 0.13 microgram/kg) for 5-9 yr, presenting with effort dyspnea and symptoms of adrenergic overactivity, and 10 matched control subjects. The patients were reassessed after 4 months of administration of the selective beta-adrenergic blocker bisoprolol (4.25 +/- 0.4 mg/day); L-T4 therapy remained unchanged. The results showed that at rest, left ventricular diastolic filling was impaired in the patients (P < 0.05), whereas systolic function was unaltered. During submaximal physical exercise, left ventricular ejection fraction increased in the controls from 58 +/- 2% to 65 +/- 2% (P < 0.001), whereas in the patients it fell from 63 +/- 2% to 53 +/- 2% (P < 0.01), mainly because of increased end-systolic left ventricular volume (P < 0.05). Exercise capacity was markedly reduced in the patients in terms of both peak workload (P < 0.001) and exercise duration (P < 0.001). beta-Adrenergic blockade prevented both the fall in ejection fraction and the increase in end-systolic volume during exercise, and improved exercise tolerance. In conclusion, our data show that long term TSH-suppressive therapy with L-T4 is not as harmless as believed, because it may cause marked impairment of cardiac functional reserve and physical exercise capacity. Administration of a beta-blocking drug for 4 months caused significant improvement of cardiac performance and exercise tolerance.
This article has been cited by other articles:
 |
|
 |
|
  M. Salerno, U. Oliviero, T. Lettiero, V. Guardasole, D. M. Mattiacci, L. Saldamarco, D. Capalbo, A. Lucariello, L. Sacca, and A. Cittadini Long-Term Cardiovascular Effects of Levothyroxine Therapy in Young Adults with Congenital Hypothyroidism J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2486 - 2491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Biondi and D. S. Cooper The Clinical Significance of Subclinical Thyroid Dysfunction Endocr. Rev., February 1, 2008; 29(1): 76 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Iqbal, H. Schirmer, P. Lunde, Y. Figenschau, K. Rasmussen, and R. Jorde Thyroid Stimulating Hormone and Left Ventricular Function J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3504 - 3510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Cooper Approach to the Patient with Subclinical Hyperthyroidism J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 3 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. A. Smit, C. F. A. Eustatia-Rutten, E. P. M. Corssmit, A. M. Pereira, M. Frolich, G. B. Bleeker, E. R. Holman, E. E. van der Wall, J. A. Romijn, and J. J. Bax Reversible Diastolic Dysfunction after Long-Term Exogenous Subclinical Hyperthyroidism: A Randomized, Placebo-Controlled Study J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6041 - 6047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kahaly and W. H. Dillmann Thyroid Hormone Action in the Heart Endocr. Rev., August 1, 2005; 26(5): 704 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Casu, C. Cappi, V. Patrone, E. Repetto, M. Giusti, F. Minuto, and G. Murialdo Sympatho-vagal control of heart rate variability in patients treated with suppressive doses of L-thyroxine for thyroid cancer Eur. J. Endocrinol., June 1, 2005; 152(6): 819 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dorr, B. Wolff, D. M. Robinson, U. John, J. Ludemann, W. Meng, S. B. Felix, and H. Volzke The Association of Thyroid Function with Cardiac Mass and Left Ventricular Hypertrophy J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 673 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Biondi, E. A. Palmieri, M. Klain, M. Schlumberger, S. Filetti, and G. Lombardi Subclinical hyperthyroidism: clinical features and treatment options Eur. J. Endocrinol., January 1, 2005; 152(1): 1 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E H Hoogendoorn, M den Heijer, A P J van Dijk, and A R Hermus Subclinical hyperthyroidism: to treat or not to treat? Postgrad. Med. J., July 1, 2004; 80(945): 394 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Helfand Screening for Subclinical Thyroid Dysfunction in Nonpregnant Adults: A Summary of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, January 20, 2004; 140(2): 128 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. I. Surks, E. Ortiz, G. H. Daniels, C. T. Sawin, N. F. Col, R. H. Cobin, J. A. Franklyn, J. M. Hershman, K. D. Burman, M. A. Denke, et al. Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management JAMA, January 14, 2004; 291(2): 228 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fazio, E. A. Palmieri, G. Lombardi, and B. Biondi Effects of Thyroid Hormone on the Cardiovascular System Recent Prog. Horm. Res., January 1, 2004; 59(1): 31 - 50. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Sgarbi, F. G. Villaca, B. Garbeline, H. E. Villar, and J. H. Romaldini The Effects of Early Antithyroid Therapy for Endogenous Subclinical Hyperthyroidism in Clinical and Heart Abnormalities J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1672 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Biondi, E. A. Palmieri, G. Lombardi, and S. Fazio Effects of Subclinical Thyroid Dysfunction on the Heart Ann Intern Med, December 3, 2002; 137(11): 904 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Wemeau, P. Caron, C. Schvartz, J.-L. Schlienger, J. Orgiazzi, C. Cousty, and V. Vlaeminck-Guillem Effects of Thyroid-Stimulating Hormone Suppression with Levothyroxine in Reducing the Volume of Solitary Thyroid Nodules and Improving Extranodular Nonpalpable Changes: A Randomized, Double-Blind, Placebo-Controlled Trial by the French Thyroid Research Group J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4928 - 4934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. PINTO and M. GLICK Management of patients with thyroid disease: Oral health considerations J Am Dent Assoc, July 1, 2002; 133(7): 849 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Toft Subclinical Hyperthyroidism N. Engl. J. Med., August 16, 2001; 345(7): 512 - 516. [Full Text] [PDF]
|
|
|
|
|
|
B. Biondi, E. A. Palmieri, S. Fazio, C. Cosco, M. Nocera, L. Saccà, S. Filetti, G. Lombardi, and F. Perticone Endogenous Subclinical Hyperthyroidism Affects Quality of Life and Cardiac Morphology and Function in Young and Middle-Aged Patients J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4701 - 4705. [Abstract] [Full Text]
|
|
|
|
 |
|
 A D Toft and N A Boon GENERAL CARDIOLOGY: Thyroid disease and the heart Heart, October 1, 2000; 84(4): 455 - 460. [Full Text]
|
|
|
|
|
|
G. Mercuro, M. G. Panzuto, A. Bina, M. Leo, R. Cabula, L. Petrini, F. Pigliaru, and S. Mariotti Cardiac Function, Physical Exercise Capacity, and Quality of Life during Long-Term Thyrotropin-Suppressive Therapy with Levothyroxine: Effect of Individual Dose Tailoring J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 159 - 164. [Abstract] [Full Text]
|
|
|
|
|
|
F. Zelmanovitz, S. Genro, and J. L. Gross Suppressive Therapy with Levothyroxine for Solitary Thyroid Nodules: A Double-blind Controlled Clinical Study and Cumulative Meta-analyses J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3881 - 3885. [Abstract] [Full Text]
|
|
|
|
|
|
E. Papini, L. Petrucci, R. Guglielmi, C. Panunzi, R. Rinaldi, V. Bacci, A. Crescenzi, F. Nardi, R. Fabbrini, and C. M. Pacella Long-Term Changes in Nodular Goiter: A 5-Year Prospective Randomized Trial of Levothyroxine Suppressive Therapy for Benign Cold Thyroid Nodules J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 780 - 783. [Abstract] [Full Text]
|
|
|
|
|
|
L. E. Shapiro, R. Sievert, L. Ong, E. L. Ocampo, R. A. Chance, M. Lee, M. Nanna, K. Ferrick, and M. I. Surks Minimal Cardiac Effects in Asymptomatic Athyreotic Patients Chronically Treated with Thyrotropin-Suppressive Doses of L-Thyroxine J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2592 - 2595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 ADVERSE EFFECTS OF CHRONIC SUPPRESSIVE THYROID THERAPY Journal Watch (General), December 31, 1996; 1996(1231): 6 - 6. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
